Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest newsInnovation3 ways Johnson & Johnson is innovating to help fight tuberculosis
      lede-3 Ways Johnson & Johnson Is Innovating to Help Fight Tuberculosis.jpg

      3 ways Johnson & Johnson is innovating to help fight tuberculosis

      It’s one of the world’s deadliest infectious diseases, killing more people each year than HIV/AIDS and malaria combined. We’re taking a look back at the strides the company has made in fighting this preventable illness to help bring us closer to a tuberculosis-free world.

      Share Article
      share to

      1.4 million. That’s how many people tuberculosis (TB) killed in 2019, despite it being a preventable and treatable disease.

      For years, one of the biggest impediments to global efforts to tackle TB has been growing resistance to the most commonly used medicines to treat the disease—in 2019 alone, there were nearly 400,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most commonly-used TB medications currently available.

      There’s also the hurdle of diagnosis: While detection numbers had been on the rise prior to the COVID-19 pandemic, there are still approximately 3 million people living with TB who don’t know they have the disease. And every individual who remains untreated can infect up to 15 additional people over the course of a year, further fueling the TB pandemic.

      COVID-19 is also posing new challenges. Not only do people with TB fear that they may be uniquely vulnerable to severe complications from COVID-19 if infected, but the pandemic has also disrupted already stretched systems of delivering TB care.

      “COVID-19 is threatening hard-won gains in the fight against TB,” says Ana-Maria Ionescu, TB Access Strategy & Impact Leader, Global Public Health, Johnson & Johnson. “At Johnson & Johnson, we are committed to doing our part, in collaboration with governments and partners, to ensure that patients continue to receive the care they need during these unprecedented times.”

      For example, in response to COVID-19, Johnson & Johnson launched the DR-TB Lifeline QuickFire Challenge, which is providing support to five organizations working to ensure continuity of care for drug-resistant TB (DR-TB) patients in India, the Philippines, South Africa and Ukraine.

      Before the pandemic, Johnson & Johnson also launched a historic 10-year initiative in 2018 aimed at helping improve disease detection; broaden access to its novel medicine for MDR-TB; and accelerate research to develop more next-generation medicines.

      It’s a critical project—and the company is well on its way to delivering on some of the key commitments.

      We’re highlighting some of the strides Johnson & Johnson made through the initiative to help bring us closer to a TB-free world.


      Johnson & Johnson’s Quest to End TB

      Read about how the company is working to improve detection, broaden access to treatment, and accelerate research and development for the disease over the next decade.

      More from Johnson & Johnson

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      How robots are helping personalize knee replacement surgery

      For Arthritis Awareness Month, learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes.

      “I couldn’t speak, walk or sit.” Inside a rare autoimmune disease that attacks the muscles

      Elisa Glass was diagnosed with dermatomyositis, which causes severe muscle weakness throughout the body. For Myositis Awareness Month, she shares her story.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.